Voyager Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
VYGR$1.83-8.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(amounts in thousands, except share data)
| | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · · · | ||||||||||||||||||
| · · · · · · · · · · Accumulated · · · · · · | ||||||||||||||||||
| · · · · · · · Additional · · Other · · · · · | ||||||||||||||||||
| · · Common Stock · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’ | ||||||||||||||||||
| · Shares · Amount · Capital · (Loss) Income · Deficit · Equity | ||||||||||||||||||
| Balance at December 31, 2021 | | 37,918,395 | | $38 | | $442,259 | | $(138) | | $(347,104) | | $95,055 | | |||||
| Exercises of vested stock options | | 89,012 | | | — | | | 629 | | | — | | | — | | | 629 | |
| Vesting of restricted stock units | | 456,219 | | | — | | | — | | | — | | | — | | | — | |
| Issuance of common stock under ESPP | | 150,265 | | | — | | | 672 | | | — | | | — | | | 672 | |
| Stock-based compensation expense | | — | | | — | | | 9,153 | | | — | | | — | | | 9,153 | |
| Unrealized loss on available-for-sale securities | | — | | | — | | | — | | | (81) | | | — | | | (81) | |
| Net loss | | — | | | — | | | — | | | — | | | (46,408) | | | (46,408) | |
| Balance at December 31, 2022 | | 38,613,891 | | $38 | | $452,713 | | $(219) | | $(393,512) | | $59,020 | | |||||
| Exercises of vested stock options | | 385,655 | | | 1 | | | 1,851 | | | — | | | — | | | 1,852 | |
| Vesting of restricted stock units | | 531,560 | | | — | | | — | | | — | | | — | | | — | |
| Issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement | | 4,395,588 | | | 5 | | | 31,116 | | | — | | | — | | | 31,121 | |
| Issuance of common stock under ESPP | | 111,639 | | | — | | | 959 | | | — | | | — | | | 959 | |
| Stock-based compensation expense | | — | | | — | | | 10,867 | | | — | | | — | | | 10,867 | |
| Unrealized gain on available-for-sale securities | | — | | | — | | | — | | | 171 | | | — | | | 171 | |
| Net income | | — | | | — | | | — | | | — | | | 132,330 | | | 132,330 | |
| Balance at December 31, 2023 | | 44,038,333 | | $44 | | $497,506 | | $(48) | | $(261,182) | | $236,320 | | |||||
| Exercises of vested stock options | | 106,831 | | | — | | | 388 | | | — | | | — | | | 388 | |
| Vesting of restricted stock units | | 515,303 | | | 1 | | | — | | | — | | | — | | | 1 | |
| Issuance of common stock in connection with the 2023 Novartis Stock Purchase Agreement | | 2,145,002 | | | 2 | | | 19,303 | | | — | | | — | | | 19,305 | |
| Issuance of common stock and pre-funded warrants in connection with underwritten public offering | | 7,777,778 | | | 8 | | | 93,465 | | | — | | | — | | | 93,473 | |
| Issuance of common stock under ESPP | | 148,069 | | | — | | | 1,172 | | | — | | | — | | | 1,172 | |
| Stock-based compensation expense | | — | | | — | | | 14,462 | | | — | | | — | | | 14,462 | |
| Unrealized loss on available-for-sale securities | | — | | | — | | | — | | | (359) | | | — | | | (359) | |
| Net loss | | — | | | — | | | — | | | — | | | (65,002) | | | (65,002) | |
| Balance at December 31, 2024 | | 54,731,316 | | $55 | | $626,296 | | $(407) | | $(326,184) | | $299,760 | | |||||
The accompanying notes are an integral part of these consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.